Takeda Pharmaceutical (TAK) Long-Term Deferred Tax (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Long-Term Deferred Tax of $3.4 billion for Q2 2026, up 22.04% year-over-year from $2.8 billion in Q2 2025, and down 2.89% quarter-over-quarter from $3.5 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Long-Term Deferred Tax (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Long-Term Deferred Tax history runs 10 years deep, the most recent figure standing at $3.4 billion for Q2 2026.
- In Q2 2026, Long-Term Deferred Tax rose 22.04% year-over-year to $3.4 billion; the TTM figure through Jun 2026 stood at $3.4 billion (up 22.04% YoY), while the FY2026 annual figure was $3.6 billion, up 49.1% from the prior year.
- Long-Term Deferred Tax for Q2 2026 stood at $3.4 billion, down from $3.5 billion in the prior quarter.
- The five-year high for Long-Term Deferred Tax was $3.5 billion in Q1 2026, with the low at $2.1 billion in Q4 2023.
- The 5-year median for Long-Term Deferred Tax is $2.7 billion (2023), against an average of $2.7 billion.
- The sharpest annual moves came in 2023 and 2026: Long-Term Deferred Tax slipped 18.55% in 2023, then jumped 43.34% in 2026.
- Takeda Pharmaceutical's Long-Term Deferred Tax stood at $2.5 billion in 2022, then fell by 15.78% to $2.1 billion in 2023, then increased by 15.52% to $2.5 billion in 2024, then advanced by 12.23% to $2.8 billion in 2025, then increased by 21.77% to $3.4 billion in 2026.
- Business Quant data shows TAK's Long-Term Deferred Tax at $3.4 billion in Q2 2026, $3.5 billion in Q1 2026, and $2.8 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Alkermes | 8.07 Bn | 7.41 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.38 Bn |
| Mar 31, 2026 | 3.48 Bn |
| Dec 31, 2025 | 2.78 Bn |
| Sep 30, 2025 | 2.65 Bn |
| Jun 30, 2025 | 2.77 Bn |
| Mar 31, 2025 | 2.43 Bn |
| Dec 31, 2024 | 2.47 Bn |
| Sep 30, 2024 | 2.27 Bn |
| Jun 30, 2024 | 2.45 Bn |
| Mar 31, 2024 | 2.66 Bn |
| Dec 31, 2023 | 2.14 Bn |
| Sep 30, 2023 | 2.33 Bn |
| Jun 30, 2023 | 2.74 Bn |
| Mar 31, 2023 | 2.77 Bn |
| Dec 31, 2022 | 2.54 Bn |
| Sep 30, 2022 | 2.86 Bn |
| Jun 30, 2022 | 2.98 Bn |
| Mar 31, 2022 | 3.12 Bn |
| Dec 31, 2021 | 3.10 Bn |
| Sep 30, 2021 | 3.05 Bn |